Corcept Therapeutics Faces FDA Rejection of Relacorilant for Cushing's Syndrome, Investor Lawsuit Filed

Key Takeaways

• FDA rejected Corcept’s relacorilant application on December 31, 2025, citing insufficient benefit-risk evidence for Cushing’s syndrome treatment
• Investor class action lawsuit alleges material misrepresentation between Corcept’s public confidence and private FDA communications
• The regulatory setback affects Corcept’s next-generation glucocorticoid receptor antagonist, while existing mifepristone franchise remains unaffected

---

FDA Delivers Major Setback to Corcept’s Relacorilant Program

Corcept Therapeutics (NASDAQ: CORT) disclosed on December 31, 2025, that the FDA issued a Complete Response Letter (CRL) rejecting the company’s New Drug Application for relacorilant, a next-generation treatment for Cushing’s syndrome. The regulatory agency concluded it could not establish a favorable benefit-risk assessment due to an “insufficient” evidentiary record.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for cushing's syndrome, with relacorilant most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Legal Challenges Mount Following Regulatory Rejection

The FDA rejection has triggered investor litigation, with a class action lawsuit alleging securities fraud. The legal action centers on claims that Corcept maintained public confidence in relacorilant’s regulatory prospects while privately receiving concerning feedback from the FDA during the review process.

Investors with substantial losses are being invited to participate in the class action, which seeks to recover damages for alleged material misrepresentations about the drug’s approval timeline and regulatory standing.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Competitive Landscape

Relacorilant was positioned as Corcept’s next-generation glucocorticoid receptor antagonist, designed to improve upon the company’s existing Cushing’s syndrome treatment, mifepristone (Korlym). The drug was expected to offer enhanced efficacy and potentially fewer side effects for patients with this rare endocrine disorder.

The rejection represents a significant blow to Corcept’s growth strategy, as relacorilant was viewed as a key pipeline asset. However, the company’s existing mifepristone franchise continues to generate revenue in the Cushing’s syndrome market, competing against treatments like pasireotide and ketoconazole.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for cushing's syndrome pricing, access, and launch sequencing.

Regulatory Path Forward Remains Uncertain

Complete Response Letters typically outline specific deficiencies that must be addressed before resubmission. While Corcept has not detailed the FDA’s specific concerns, the “insufficient evidentiary record” suggests the agency may require additional clinical data to support the drug’s benefit-risk profile.

The company will need to evaluate whether to conduct additional studies, modify the proposed indication, or pursue alternative regulatory strategies. This process could delay any potential approval by several years and require substantial additional investment.

IntelligenceStrategic Takeaways▾

FDA rejected Corcept’s relacorilant application on December 31, 2025, citing insufficient benefit-risk evidence for Cushing’s syndrome treatment Investor class action lawsuit alleges material misrepresentation between Corcept’s public confidence and private FDA communications The regulatory setback affects Corcept’s next-generation glucocorticoid receptor antagonist, while existing mifepristone franchise remains unaffected

Implications for Cushing’s Syndrome Treatment

Cushing’s syndrome affects a relatively small patient population, making it a rare disease with limited treatment options. The rejection of relacorilant means patients will continue relying on existing therapies while awaiting next-generation treatments.

The setback also highlights the challenges of developing treatments for rare endocrine disorders, where clinical trial design and regulatory requirements can be particularly complex due to small patient populations and varied disease presentations.

---

Frequently Asked Questions

What does the FDA rejection mean for Cushing’s syndrome patients?

Patients will continue using existing treatments like mifepristone (Korlym), pasireotide, and ketoconazole while Corcept determines next steps for relacorilant, which could include additional clinical studies and resubmission.

When might relacorilant become available if Corcept resubmits?

The timeline is uncertain and depends on FDA’s specific requirements. If additional clinical studies are needed, approval could be delayed by 2-4 years from the original timeline.

How does this affect Corcept’s existing Cushing’s syndrome business?

Corcept’s current mifepristone (Korlym) franchise remains unaffected by the relacorilant rejection and continues to serve patients with Cushing’s syndrome, providing ongoing revenue for the company.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• relacorilant

Related coverage

• Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context
• Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026
• Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide